F. Lam

发表

Discovery and evaluation of anti-cancer agents

F. Lam, 2010 .

Microsoft Word-48900873-file00.docx

Sunita K. C. Basnet, F. Lam, M. Sykes, 2015 .

Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.

P. Fischer, Shudong Wang, F. Lam, 2021, European journal of medicinal chemistry.

Targeting CDK9 for treatment of colorectal cancer

C. Ricciardelli, N. Lokman, Shudong Wang, 2019, Molecular Oncology.

Targeting CDK9 for treatment of colorectal cancer

C. Ricciardelli, N. Lokman, Shudong Wang, 2019, Molecular oncology.

Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73

Yi Chen, P. Fischer, Jian Ding, 2014, Oncotarget.

Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.

P. Fischer, Shudong Wang, Xiangrui Liu, 2013, European journal of medicinal chemistry.

Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.

Shudong Wang, Xiangrui Liu, F. Lam, 2012, European journal of medicinal chemistry.

In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83

P. Fischer, Shudong Wang, Xiangrui Liu, 2012, Investigational New Drugs.

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.

Shudong Wang, F. Lam, M. Sykes, 2015, Cancer letters.

Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide.

Wei Zhang, D. Brooks, F. Lam, 2016, International journal of pharmaceutics.

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Shudong Wang, F. Lam, R. Milne, 2018, Investigational New Drugs.

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities

M. Noble, J. Endicott, P. Fischer, 2013, Journal of Medicinal Chemistry.

ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities

Shudong Wang, F. Lam, T. Bradshaw, 2012, Investigational New Drugs.

Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3H)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation

Sunita K. C. Basnet, Shudong Wang, P. Li, 2014, ChemMedChem.

Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.

C. Midgley, Shudong Wang, Xiangrui Liu, 2014, Journal of Medicinal Chemistry.

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin‐dependent kinases 4 and 6 as anticancer agents

Shudong Wang, F. Lam, Malika Kumarasiri, 2018, British journal of pharmacology.

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Sunita K. C. Basnet, Shudong Wang, F. Lam, 2017, Journal of medicinal chemistry.

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

Theodosia Teo, Mingfeng Yu, Sunita K. C. Basnet, 2015, Molecular Pharmacology.

Targeting Mnks for Cancer Therapy

C. Proud, Shudong Wang, F. Lam, 2012, Oncotarget.

CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol

P. Fischer, Shudong Wang, Xiangrui Liu, 2012, International journal of cancer.

Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors.

C. Midgley, Shudong Wang, F. Lam, 2011, Bioorganic & medicinal chemistry letters.

Substituted 4-(Thiazol-5-Yl)-2-(Phenylamino)Pyrimidines are Highly Active Cdk9 Inhibitors: Synthesis, X-Ray Crystal Structure, Sar and Anti-Cancer Activities.

M. Noble, J. Endicott, P. Fischer, 2013 .

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.

Shudong Wang, F. Lam, M. Sykes, 2015, Cancer letters.

CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol

P. Fischer, Shudong Wang, Xiangrui Liu, 2012, International journal of cancer.

Discovery and Pharmacological Characterisation of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents Running Title Highly Selective CDK 4 / 6 Inhibitors as Anticancer Agents

Shudong Wang, F. Lam, Malika Kumarasiri, 2017 .